Updated Jul 16, 2026
LAPORTE KATHLEEN has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $123K.
Kathleen Laporte is a corporate director involved with several biotechnology companies, including Bolt Biotherapeutics, Inc. and Precipio, Inc. She has participated in multiple SEC filings, indicating her active role in corporate governance.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-10-15 | PRPO | Precipio, Inc. | A — Grant or award | 711 | $17.58 | $12K |
| 2025-09-08 | PRPO | Precipio, Inc. | S — Open-market sale | 6.2K | $20.06 | $123K |
| 2025-04-15 | PRPO | Precipio, Inc. | A — Grant or award | 2.2K | $5.60 | $12K |
| 2024-10-02 | CERO | CERO THERAPEUTICS HOLDINGS, INC. | M — Option exercise | 966.0K | — |
Kathleen Laporte is a corporate director involved with several biotechnology companies, including Bolt Biotherapeutics, Inc. and Precipio, Inc. She has participated in multiple SEC filings, indicating her active role in corporate governance.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($123K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live LAPORTE KATHLEEN profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.